Excited to share full data for BEAM-301 in GSD1a, covering the first two dose cohorts ** Importantly, 2/3 patients at the 2nd dose level achieved maximum fasting duration and no longer require corn starch supplementation after a single dose of BEAM-301 globenewswire.com/news-relea…

Great interview by @statnews with @moderna_tx CEO Stephane Bancel. I’ve had this feeling before for RNAi: “It was always clear to me that mRNA was going to work for nothing, or a lot of things.”

Wonderful in-depth story here from Bloomberg @business about Beam’s efforts to provide a one-time genetic correction for Alpha-1 Antitrypsin Deficiency (BEAM-302) Amazingly, author Gary Sernovitz is himself an Alpha-1 patient, who is learning about this genetic disease and the emerging options in development to treat it I really enjoyed getting to know Gary, who brought so much curiosity and perspective to researching this story His inspiring conclusion, finding himself recently diagnosed with a genetic condition that now sits at the frontier of a new kind of medicine: “I find myself in a cohort who worry about our liver and lungs… and who are the ideal pioneers for a mind-boggling medical advance. I suspect many are like me, eager to put our body to the test and accept our unasked-for role in the history of gene editing. We have good luck in our bad luck.” (subscription required) bloomberg.com/news/features/…